Home/Pipeline/Remestemcel-L

Remestemcel-L

Acute Respiratory Distress Syndrome (ARDS)

Phase 3ActiveNCT04371393

Key Facts

Indication

Acute Respiratory Distress Syndrome (ARDS)

Phase

Phase 3

Status

Active

Company

Mesoblast, Mesoblast

About Mesoblast

Mesoblast is a pioneering Australian biotechnology company with a mission to transform patient outcomes through its proprietary allogeneic mesenchymal lineage cell technology platform. Its key achievement is the FDA approval and commercialization of RYONCIL for pediatric steroid-refractory acute graft-versus-host disease, marking it as a first-in-class therapy. The company's strategy leverages this validated platform to expand into large market opportunities in chronic low back pain, heart failure, and other inflammatory conditions, aiming to establish a new paradigm in regenerative medicine.

View full company profile

About Mesoblast

View full company profile

Therapeutic Areas

Hematology/Oncology Cardiovascular Orthopedic Immunology

Other Acute Respiratory Distress Syndrome (ARDS) Drugs

Drug	Company	Phase	Status
MultiStem	Athersys	Phase 3	Active (subject to funding)
BXT-25	BioXyTran	Preclinical	Active
Bioengineered Surfactant Program	BioSuperior	Pre-clinical	Active
FX06	F4 Pharma	Phase 1/2	Active
AVM0703	AVM Biotechnology	Pre-clinical / Research	Active
ACE2v2-Fc	Cyrus Biotechnology	Preclinical	Active
GEn-1124	GEn1E Lifesciences	Phase 2	Active
AZM-152	Azome Therapeutics	Pre-clinical	Active
Zelpultide Alfa	Airway Therapeutics	Pre-clinical/Research	Active
ALT-100 mAb	Aqualung Therapeutics	Phase 2a	Active
RP-323	PhorMed	Phase 2	Active
Research Grant: Effect of volatile sedation on spontaneous breathing in ARDS	Sedana Medical	Investigator-Initiated Trial	Active